Lifeboat Foundation

𝐀 𝐝𝐫𝐮𝐠 𝐭𝐡𝐚𝐭 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐞𝐬 𝐝𝐨𝐩𝐚𝐦𝐢𝐧𝐞 𝐜𝐚𝐧 𝐫𝐞𝐯𝐞𝐫𝐬𝐞 𝐭𝐡𝐞 𝐞𝐟𝐟𝐞𝐜𝐭𝐬 𝐨𝐟 𝐢𝐧𝐟𝐥𝐚𝐦𝐦𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐭𝐡𝐞 𝐛𝐫𝐚𝐢𝐧 𝐢𝐧 𝐝𝐞𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧, 𝐄𝐦𝐨𝐫𝐲 𝐬𝐭𝐮𝐝𝐲 𝐬𝐡𝐨𝐰𝐬

𝘼𝙣 𝙀𝙢𝙤𝙧𝙮 𝙐𝙣𝙞𝙫𝙚𝙧𝙨𝙞𝙩𝙮 𝙨𝙩𝙪𝙙𝙮 𝙥𝙪𝙗𝙡𝙞𝙨𝙝𝙚𝙙 𝙞𝙣 𝙉𝙖𝙩𝙪𝙧𝙚’𝙨 𝙈𝙤𝙡𝙚𝙘𝙪𝙡𝙖𝙧 𝙋𝙨𝙮𝙘𝙝𝙞𝙖𝙩𝙧𝙮 𝙨𝙝𝙤𝙬𝙨 𝙡𝙚𝙫𝙤𝙙𝙤𝙥𝙖, 𝙖 𝙙𝙧𝙪𝙜 𝙩𝙝𝙖𝙩 𝙞𝙣𝙘𝙧𝙚𝙖𝙨𝙚𝙨 𝙙𝙤𝙥𝙖𝙢𝙞𝙣𝙚 𝙞𝙣 𝙩𝙝𝙚 𝙗𝙧𝙖𝙞𝙣, 𝙝𝙖𝙨 𝙥𝙤𝙩𝙚𝙣𝙩𝙞𝙖𝙡 𝙩𝙤 𝙧𝙚𝙫𝙚𝙧𝙨𝙚 𝙩𝙝𝙚 𝙚𝙛𝙛𝙚𝙘𝙩𝙨 𝙤𝙛 𝙞𝙣𝙛𝙡𝙖𝙢𝙢𝙖𝙩𝙞𝙤𝙣 𝙤𝙣 𝙗𝙧𝙖𝙞𝙣 𝙧𝙚𝙬𝙖𝙧𝙙 𝙘𝙞𝙧𝙘𝙪𝙞𝙩𝙧𝙮, 𝙪𝙡𝙩𝙞𝙢𝙖𝙩𝙚𝙡𝙮 𝙞𝙢𝙥𝙧𝙤𝙫𝙞𝙣𝙜 𝙨𝙮𝙢𝙥𝙩𝙤𝙣𝙨 𝙤𝙛 𝙙𝙚𝙥𝙧𝙚𝙨𝙨𝙞𝙤𝙣.

Numerous labs across the world have shown that inflammation causes reduced motivation and anhedonia, a core symptom of depression, by affecting the brain’s reward pathways.

Continue reading “A drug that increases dopamine can reverse the effects of inflammation on the brain in depression, Emory study shows” »

I never thought I’d order live human kidney cells to my address, but that all changed when I found out about biohacker Jo Zayner’s at-home genetic engineering class.

You may know Jo Zayner, a “biohacker” who has been in the vanguard of scientific self-experimentation for years, from their role in Netflix’s 2019 docuseries Unnatural Selection. The series shows Zayner attempting to edit their DNA by injecting themselves with CRISPR, a gene-editing technology. The action inspired a firestorm of criticism.

Zayner is also known for a variety of other bold moves, such as claiming to create a DIY at-home COVID vaccine in 2020 and executing their own fecal microbiome transplant.

Greater diversification could help agriculture withstand climate, economic and geopolitical crises.

“Items in this section have limited availability due to supplier production issues,” “Sorry, temporarily out of stock” and “Sold out” are all signs that became familiar as recent global upheavals exposed how precarious our food supply is.

The COVID-19 pandemic led to bare shelves in supermarkets as shipping routes were cut off. The war in Ukraine has affected the supply of essential grains.

CRISPR may be in for a fight thanks to this new, faster, safer, AI-powered zinc-finger gene-editing technique.

A new study has developed what the researchers call the “world’s first” simple, modifiable proteins. Called “zinc fingers,” these special proteins were developed partially through artificial intelligence.

Continue reading “A new AI-powered gene-editing technique could be set to replace CRISPR” »

According to the U.S. Centers for Disease Control and Prevention, more than 40% of people living in the U.S. are obese; and 43% of American women over the age of 60—long past menopause—are considered obese. A recent Johns Hopkins study showed that a drug first developed to treat Alzheimer’s disease, schizophrenia, and sickle cell disease could treat obesity and fatty liver and improve heart function—without changes in food intake or daily activity.

Is RNA next frontier in drug discovery?

Researchers from Harvard Medical School found that it is the changes that affect the expression of the DNA — called epigenetics — that affect aging. The discovery may pave the way for more insights into how humans age.

Electronic cigarette (e-cigarette) users have greater lung inflammation than cigarette smokers and non-smokers, according to a new study published online in The Journal of Nuclear Medicine. This study is the first to provide evidence that vaping e-liquids with e-cigarettes creates a unique inflammatory response in the lungs that is different from cigarette smoking.

E-cigarette usage has increased dramatically in the past several years, particularly among adolescents and young adults. While many people assume that e-cigarettes are safer than conventional cigarettes, e-cigarettes can cause pulmonary inflammation and increase the risk of lung disease. In addition, their long-term safety has not been rigorously evaluated.

This is the first PET study to use a novel radiotracer, ¹⁸ F-NOS, to compare lung inflammation between cigarette and e-cigarette users in vivo. Although PET imaging with ¹⁸ F-FDG has been used in the past to investigate inflammation in smokers and vapers, its conclusions were limited.

A monoclonal antibody treatment was found to be safe, well tolerated, and effective in protecting against malaria in a small group of healthy volunteers who were exposed to malaria in a challenge study, according to new research published in The Lancet Infectious Diseases by researchers at the University of Maryland School of Medicine (UMSOM).

“The study demonstrates the feasibility of using monoclonal antibody therapies to help prevent malarial infection and holds promise for deployment to places where the disease is endemic,” said Kirsten Lyke, MD, Professor of Medicine and Director of the Malaria Vaccine and Challenge Unit in the Center for Vaccine Development and Global Health (CVD) at UMSOM. “This may allow us to revisit malaria eradication efforts.”

There were 241 million malaria cases and 627,000 deaths reported worldwide in 2020 alone, which is a 12 percent increase from 2019. Public health experts contend new strategies are urgently needed to achieve the United Nation’s sustainable development goal of 90 percent reduction in malaria incidence and mortality by 2030. Scientists have tried for decades to develop a highly effective malaria vaccine without much success.